Premier Alternatives

Veralox Therapeutics

Frederick, MD · Founded 2017 · Privately Held (backing)

Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. Veralox Therapeutics is based in Frederick, MD and was founded in 2017. It was valued at $66 million at its later-stage round in Jun 2023, the last priced event on record. It has raised $41.2 million across 3 recorded rounds; the latest was a $24 million early-stage round in Jun 2023.

PMV mark · valuation
$66.0M
Oct 2026
Priced at
its later-stage round
Jun 2023
Total raised
$41.2M
Last round
Early Stage VC
Jun 2023

Veralox Therapeutics key facts

as of Oct 2026
  • Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis.
  • Veralox Therapeutics is valued at approximately $66.0M as of Oct 2026, set at its later-stage round, Jun 2023; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $41.2M across 3 recorded rounds; the latest was Early Stage VC ($24.0M) in Jun 2023.
  • Notable investors include Alumni Ventures, Alexandria Venture Investments, TEDCO, NYBC Ventures, Point Field Partners — 15 tracked in total.
  • Veralox Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently Jun 2023 ($24.0M sold to 14 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$66.0M

Valued at $66.0M at its later-stage round, Jun 2023. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Veralox Therapeutics with a free account
  • ·The complete investor list: 15 names
  • ·Watch Veralox Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Veralox Therapeutics funding rounds

3 rounds
Jun 2023Early Stage VC$24.0MSEC filing▮
Jun 2021Early Stage VC$14.4MSEC filing▮
May 2019Debt$1.5MSEC filing▮
Full funding history →

Veralox Therapeutics valuation

Veralox Therapeutics was valued at $66 million at its later-stage round in Jun 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Veralox Therapeutics raised?

Veralox Therapeutics has raised $41.2 million across 3 recorded rounds since 2019. The largest was a $24 million early-stage round in Jun 2023.

Veralox Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently in Jun 2023 ($24 million sold to 14 investors).

Veralox Therapeutics investors

15 investors are on record for Veralox Therapeutics, including Alumni Ventures, Alexandria Venture Investments, TEDCO and NYBC Ventures. The early-stage round in Jun 2023 drew 14 investors.

About Veralox Therapeutics

Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company's therapeutics focus on new treatment paradigms and improved outcomes for patients based on the understanding of the molecular mechanisms of diabetes diseases, enabling patients to achieve complete recovery from diabetes.

Sector
Healthcare
HQ
Frederick, MD, United States
Founded
2017
Employees
18
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.